Development And Evaluation

Of A Matrix Controlled Release Implant

System For Testosterone by Hamad, Islam
DEVELOPMENT AND EVALUATION 
OF A MATRIX CONTROLLED RELEASE IMPLANT 
SYSTEM FOR TESTOSTERONE 
By 
ISLAM HAMAD 
Nov~mber 2002 
Thesis submitted in fulfillment of the requirements of Master 
of Sciences 
BY THE NAME OF ALLAH, 
ALL-MERCIFUL, MOST BENEFICENT 
TO THOSE WHO HAVE PROVIDED THE COUNTERPOINT: MY 
PARENTS, MUSTAFA HAMAD AND FA T/MA HAMAD, AND TO ALL 
MY BROTHERS AND SISTERS 
III 
AKNOWLEDGEMENTS 
I would like to express my deep appreciation and sincere gratitude to my main supervisor 
Prof. Dr. Saringat Hj. Baie and my co-supervisor Prof. Dr. Yuen Kah Hay for leading 
me as independent researcher and for their invaluable advice and guidance throughout my 
research. I am unreservedly indebted for their unfailing encouragement in the different 
sections of the study. 
I would also like to thank all the lecturers and staff of the school of pharmacy for their 
encouragement and making the facilities of the school available all the times. Thanks also 
to the Institute of Postgraduate Studies for being very helpful in various ways. 
I wish to express my deep thanks and "Ribuan Terima Kasih" to the University of 
Science Malaysia for making the facilities available for this project. A big thank you to 
Hovid Pharmaceutical Company for their generous supply of a lot of the materials used in 
the study and also for allowing me use facilities in their lab. 
I am most grateful to Dr Wong Jia Woei who helped me in many ways and shared 
valuable discussions. Big thanks also to the folks of the Ho Y an Hor Research Laboratory 
especially to Bee Hong who at one time or other contributed to the progress of this . 
project. 
IV 
Finally, special thanks and gratitude are also due to my father, my mother and my 
relatives and friends back at home for their enthusiasm and moral support. The role they 
have played in making this project a reality will forever be remembered and appreciated. 
v 
CONTENTS 
TITLE 
DEDICATION 
ACKNOWLEDGEMENTS 
CONTENTS 
LIST OF TABLES 
LIST OF FIGURES 
ABTRAK 
ABSTRACT 
CHAPTER 1 INTRODUCTION 
1.1 Controlled release dosage forms 
1.1.1 
1.1.2 
1.1.3 
I .2 Implants 
1.2.1 
1.2.2 
General principles 
Methods to achieve controlled release of drugs 
Advantages of controlled release 
General principles 
Controlled release mechanism involved in implantable 
drug delivery system 
I .3 Dissolution of sustained release dosage forms 
VI 
Page 
II 
III 
IV 
VI 
X 
XI 
XIII 
XIV 
1 
3 
5 
7 
7 
10 
11 
I .4 Testosterone 13 
1.4.1 General pharmacology 13 
1.4.1.1 Pharmacology I3 
1.4.1.2 Pharmacokinetics 15 
1.4.1.3 Preparations 15 
1.4.1.4 Indications 16 
1.4.1.5 Adverse effect and contraindications 17 
1.4.2 Evolution of testosterone replacement therapy 17 
1.5 Experimental scope of this study 19 
CHAPTER 2 PREPARATION OF TESTOSTERONE CONTROLLED RELEASE 
IMPLANT SYSTEMS AND IN-VITRO STUDIES 
2. I Introduction 
2.2 Materials and methods 
2.2.I 
2.2.2 
2.2.2.1 
2.2.2.2 
2.2.2.3 
Materials 
Methods 
Preparation of testosterone implant systems 
Evaluation of various polymers as matrix forming 
materials 
Preparation of testosterone implant systems containing 
a combination of the polymers at different ratios 
VII 
20 
22 
22 
24 
24 
24 
25 
2.2.2.4 
2.2.2.5 
2.2.2.6 
Preparation of testosterone implant systems containing 
different drug to polymer ratios 
Preparation of testosterone implant systems containing 
different viscosity grades of HPMC 
Preparation of testosterone implant systems containing 
different amounts of SLS 
2.3 In-vitro dissolution studies 
2.4 Results and discussion 
2.4.1 Evaluation of the three polymers as matrix forming 
materials in implant systems 
2.4.2 Evaluation of testosterone implant systems containing 
combination of the polymers at different ratios 
2.4.3 Evaluation of testosterone implant systems containing 
different drug to polymer ratios 
2.4.4 Evaluation of different viscosity grades of HPMC 
2.4.5 The effect of SLS on the release of testosterone from 
the implant system 
2.5 Stability studies 
2.6 Summary and conclusion 
CHAPTER THREE IN-VIVO EVALUATION 
3 .I Introduction 
VIII 
28 
28 
31 
31 
33 
33 
35 
40 
45 
48 
52 
52 
54 
3 .2 Materials and methods 
3.2.1 Materials 
3.2.2 Study design 
3.2.3 Dissolution testing of the implant systems 
3.2.4 Implantation 
3.2.5 Blood samples 
3.2.6 Analysis of plasma samples 
3.2.7 Data analysis 
3.2.8 Statistical analysis 
3.3 Results and discussion 
3.3.1 Analysis of testosterone in plasma 
3.3.2 In-vivo performance of the formulation 
3.4 Conclusion 
CHAPTER 4 SUMMARY AND GENERAL CONCLUSION 
CHAPTER 5 SUGGESTIONS FOR FURTHER RESEARCH 
REFERENCES 
APPENDIX 
IX 
55 
55 
55 
57 
58 
63 
63 
66 
66 
66 
66 
68 
76 
77 
79 
81 
89 
LIST OF TABLES 
2.1 
2.2 
2.3 
2.4 
2.5 
2.6 
2.7 
2.8 
2.9 
3.1 
3.2 
3.3 
Formulae for testosterone implant systems containing single 
polymer 
Formulae for testosterone implant systems containing a combination 
of the three polymers 
Formulae for testosterone implant systems containing a fixed ratio of 
HPMC to starch and different drug to polymer ratios 
Formulae for testosterone implant systems containing different viscosity 
grades ofHPMC 
Formulae for testosterone implant system containing SLS 
Time for 50% release of testosterone from the polymer matrices 
containing different starch: HPMC ratios 
Time for 50% release of testosterone from different concentrations of 
HPMC matrices 
Time for 50% release of testosterone from the polymer matrices 
GOntaining different viscosity grades of HPMC 
Time for 50% release of testosterone from the polymer matrices 
containing SLS 
Weights of rats involved in the bioavailability study 
Recovery of the extraction, within-day and between-day precision and 
accuracy values of the assay method 
AUCo-63 values obtained after insertion of the two implant systems 
X 
26 
27 
29 
30 
32 
39 
42 
47 
51 
56 
65 
71 
LIST OF FIGURES Page 
I. I Chemical structure of testosterone 14 
2.1 Front view Illustration of an extruder 23 
2.2 In.,vitro release of testosterone from starch polymeric matrix 34 
2.3 In-vitro release of testosterone from implant systems containing 37 
different HPMC to starch ratios 
2.4 In-vitro release of testosterone from implant systems with and 38 
without PVP 
2.5 In-vitro release of testosterone from HPMC KIOO polymeric 41 
matrices 
2.6 In-vitro release of testosterone from different viscosity grades of 46 
HPMC 
2.7 The effect of sodium lauryl sulphate (SLS) on the release of 50 
testosterone from HPMC matrix 
2.8 ,In-vitro release of testosterone from HPMC K I 00 polymer matrix 53 
after storage for 6 months 
3.1 In-vitro release of testosterone from two formulations containing 59 
different drug to polymer ratios 
3.2 Rat implanted with the testosterone formulation 60 
3.3 The implantation of testosterone implant systems into the rat 61 
3.4 The puncture wound after being closed with surgical sutures 62-
3.5 Chromatograms of plasma samples taken from a rat before dosing 67 
(0 hour) and 1 week after administration of 80% testosterone implant 
systems 
3.6 In-vivo plasma testos~erone concentration versus time profiles from 69 
the two formulations 
3.7 In-vivo plasma testosterone concentration versus time profiles on the 70 
first two days after implantation of the two formulations 
XI 
3.8 
3.9 
Detailed 24-hr profile of plasma testosterone levels on days 7 and 45 
from implant systems containing 80% of the drug 
Detailed 24-hr profile of plasma testosterone levels on days 7 and 45 
from implant systems containing 40% of the drug. 
XII 
73 
74 
PEMBANGUNAN DAN PENILAIAN SISTEM MA TRIK SEDIAAN 
PELEPASAN BERTAHAN TESTOSTERON 
ABSTRAK 
Sistem implan yang dibuat daripada hidroksipropril metilselulosa (HPMC K I 00) dan 
kanji dengan nisbah 9:1 adalah licin serta mempunyai bentuk yang seragam dan 
kekerasan yang mencukupi. Kanji ditambah pada kepekatan yang rendah untuk 
memudahkan · ekstrusi sistem implan. Sistem implan tersebut juga mempamerkan 
pelepasan testosteron secara terkawal, di mana pelepasan yang boleh dijangka ini 
boleh diubahsuai dengan mengubah nisbah drug kepada polimer. 
Kesan HPMC dengan gred kelikatan yang berlainan dan penambahan agen aktif 
permukaan anionik ke atas profil pelepasan drug juga dinilai. HPMC dengan gred 
kelikatan yang tinggi dan penambahan natrium lauril sulfat (SLS) berkeupayaan untuk 
merencat pelepasan testosteron daripada sistem implan. 
Dua formulasi sistem implan yang berlainan juga dinilai di dalam satu kajian in vivo 
dengan menggunakan 12 ekor tikus Sprague Dawley (SD) jantan. Kedua-dua sistem 
implan tersebut mengandungi 10 mg testosteron dengan nisbah drug kepada polimer 
8:2 dan 4:6. Sepanjang jangkamasa kajian, pelepasan drug yang perlahan dan 
terkawal boleh diperhatikan. Sistem implan dengan nisbah drug kepada polimer 8:2 
mempunyai ~adar peiepasan drug lebih kurang dua kali lebih cepat daripada sistem 
implan dengan nisbah 4:6. Ini menunjukkan bahawa pelepasan drug mempunyai 
korelasi yang baik dengan kandungan polimer di dalam sistem implan dan keputusan 
ujian pelarutan in vitro. Tambahan pula, paras testosteron di dalam plasma sepanjang 
24jam boleh dikatakan seragam. 
XIII 
ABSTRACT 
Implant systems fabricated using hydroxypropyl methylcellulose (HPMC KIOO) and . 
starch at a ratio of 9: 1 were smooth and uniform in shape with adequate hardness. Starch 
was added in low concentrations to facilitate the extrusion of the implant system. The 
implant systems also displayed a controlled release of testosterone, which could be varied 
in a predictable manner bY varying the'drug to polymer ratio. 
rhe effect of different viscosity grades of HPMC and the addition of anionic surfactant 
m the release profile of the implant systems were also evaluated. Higher viscosity grades 
,f HPMC and the addition of sodium Iaury! sulphate (SLS) were capable of further 
etarding the release of testosterone from the implant system. 
'wo formulations of the implant systems were further evaluated in an in-vivo study using 
-velve Sprague Dawley (SD) male rats. Both formulations contained 10 mg of 
:stosterone with drug to polymer ratios of 8: 2 and 4: 6. A slow and sustained release of 
:stosterone was observed after the implantation and during the entire study period. The 
:te of testosterone release from implant system with 8: 2 drug to polymer ratio was 
>proximately two times higher than that with 4: 6 drug to polymer ratio; thus indicating 
at the release was highly correlated with the polymer content in the formulation as well 
the in-vitro dissolution results. Moreover, plasma testosterone levels throughout the 24 
1urs were reasonably constant throughout the day period. 
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CHAPTER ONE 
INTRODUCTION 
1.1 CONTROLLED RELEASE DOSAGE FORMS 
1.1.1 GENERAL PRINCIPLES 
Conventional drug delivery systems are primary pharmaceutical products that are designed 
to provide· a prompt release of drug, thus, giving a maximum rate and extent of absorption. 
However, multiple daily dosing is required and wide fluctuations in plasma levels are often 
observed with these products, thus making it undesirable with drugs for chronic diseases 
such as asthma and male hypogonadism as well as drugs with narrow therapeutic indices. 
In such instances, ·sustained release dosage forms or controlled release dosage forms 
appeared to be a more attractive mean for delivering drugs into the systemic circulation 
(Zaffaroni, 1980). 
Sustained release dosage forms are drug delivery systems designed to retard the release of 
drug such that its appearance in the systemic circulation is delayed or prolonged and hence, 
the drug concentrations are maintained in the blood over an extended period of time. 
1 
Controlled release dosage forms, on the other hand, are formulated to release drug at a 
precise rate profile that is kinetically predictable and reproducible froin one unit to another 
(Chien, 1992). The drug is ideally released at a zero-order rate to obtain a constant plasma 
concentration over prolonged periods of time (Hussain et al., 1984). 
Many attempts have been made to obtain a suitable controlled drug release system, which is 
capable of maintaining a sustained drug level in plasma or target tissue. One of the earliest 
orally extended release dosage forms was Spansule® capsule, which was introduced in 1945 
by ·Smith, Kline and French Laboratories (SK&F). It was designed to release the 
therapeutic agent at rates independent of the gastrointestinal environment. In 1950, Saunder 
et al suggested that the extended release of ionizable drug could be obtained by binding it 
with an ion exchange resin. Swintosky in 1959 introduced the first liquid preparation of 
extended release dosage form for oral administration, while Ostholm and Sandell also 
patented a tablet containing plastic matrix (Javaid, 1996). One of the earliest attempts 
toward producing a controlled release dosage form was done by the German dermatologist, 
Unna in 1884, he found that the release of the drug from the tablets took place in the 
intestine and would not dissolve in gastric acid· flttid (Helfand and Cowen, 1982; Mumtaz, 
1993). 
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1.1.2 METHODS TO ACHIEVE CONTROLLED RELEASE OF DRUGS 
There are a variety of methods to control the release of drug from a dosage form. The 
determining factors in selecting a particular technique include cost, the potency and the 
properties of the drug, the requirement for biodegradability of the polymers and most 
importantly, the release rate desired. 
In general, controlled release of drug can be obtained through chemical and pharmaceutical 
means (Lordi, 1986). The former is based on modification of those physical and/or 
chemical properties of the drug that affect bioavailability. These include the use of complex 
formation, ion-exchange resins to form drug adsorbates, and prodrug synthesis. The 
mechanism ?f sustained drug release is through decreased rate of dissolution of the altered 
drug and/or dissociation of the free drug into solution. In the case of prodrugs, a slow 
regeneration of the parent compound after absorption may provide an additional strategy 
for prolonging the drug action. The resulting d~g modifications can thus be formulated as 
liquid suspensions, capsules or tablets. However, these methods can only be applied to drug 
moieties containing the appropriate functional groups (Yuen, 1991 ). 
The second set of methods is based on modification of the drug release characteristics of 
the dosage form. Although products based on dosage form modification are of many 
designs and constructions, the mechanisms underlying the sustained release are few (Lee 
and Robinson, 1978). Drugs that are slowly dissolving are inherently sustained, but those 
3 
with rapid dissolution rates can be retarded by various means such as embedding them in a 
non-soluble, slowly soluble or hydrophilic matrix system, which may be then encapsulated 
in particulat~ form or compressed into tablets. Drug that is trapped in the· channels of the 
'• 
porous insoluble matrix is released in-vivo upon penetration of fluids from the 
gastrointestinal tract. The dissolved molecules then diffuse out from these channels out 
from the matrix. The release mechanism of such system has been well studied by Higuchi 
in 1963. On the other hand, the drug release from the slowly soluble matrix system occurs 
through a combination of factors, such as permeation of the matrix by dissolution medium 
and erosion of the matrix material. 
On the other hand, hydrophilic matrix consists of materials that swell and form gels upon 
contact with water or gastrointestinal fluids. Drug release in such system is controlled by 
the leaching/diffusion of the active substances through the swollen hydrated matrix, in 
addition to the erosion of the gelled layer. 
An important class of the hydrophilic matrix former is hydrogel. It is defined as a natural or 
synthetic polymer that is capable of swelling in water and retaining a considerable amount 
of water without dissolving in it (Breimer et al., 198 5). For example, hydroxypropyl methyl 
cellulose (HPMC) has a unique ability to form hydrogel and thus offers a reliable method 
of regulating the drug release. The release of the drug from the gel can also be modified by 
the use of surfactant (Saito, 1960), varying the amount of the polymer in the formulation 
(Xu and Sunada, 1995), as well as using different viscosity grades of the hydrogel (Lapidus 
and Lordi, 1968; Daly et al., 1984). 
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One new method for controlling the drug release is through osmotic pump, which utilizes 
osmotic pressure to co.ntrol the release of active agents (Eckenhoff et al., 1981; Theeuwas 
et al., 1980). More recently, the osmotic pumps are small enough to be made implantable. 
The built-up of the osmotic pressure in the pump is attributed to the diffusion of water 
across a semipermeable membrane and dissolving the salt inside. The resulting solution 
pushes the active agent from the device. The rate of drug release will remain constant as 
long as the excess active drug remains within the device. Since the system is based upon 
osmotic pressure, the drug is delivered at a rate that is essentially independent on 
environmental pH and stirring rate. Example for a commercial oral osmotic pumping drug 
delivery system is OROS® which is being marketed by ALZA Corporation U.S.A. 
(Godbillon et al., 1985a). 
1. ~ .3 ADVANTAGES OF CONTROLLED RELEASE 
Controlled release delivery systems offer four principal advantages over conventional 
formulations that deliver the entire active drug over a short period of time. The first 
advantage is that it provides a more constant drug level in the systemic circulation, and thus 
maintaining the concentration of the drug between the minimum effective and toxic levels. 
Such control is inherently difficult with conventional formulations, which tend to overdose 
initially and the subsequent blood levels fall below the minimum therapeutic levels. Thus, 
controlled release systems are designed in which the rate of drug delivery into the systemic 
circulation follows its rate of removal (Theeuwes, 1983). 
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Controlled release drug delivery systems are also capable of prolonging the therapeutic 
level of drug in the blood beyond that achieved with conventional dosage forms. The 
frequency of drug administration could be reduced to either once or twice daily; resulting in 
significantly improved patient convenience and compliance. The medical profession widely 
recognizes that a once-daily dosage regimen leads to significantly better patient compliance 
than multiple daily dosing, with a consequent improvement in the efficacy of the treatment 
(Brooks et al., 1980). · 
Another important benefit is the elimination of local gastrointestinal irritation and erosion 
arising from exposure of the gastric mucosa to high drug concentrations released from the 
conventional dosage forms. Additionally, the systemic side effects could also be 
·circumvented due to the absence of supra-therapeutic blood levels (Cowsar, 1974; Baker et 
a!., 1979). 
Moreover, in view of the constant rate of drug delivery, controlled release systems require a 
smaller amount of drug to produce therapeutic blood level for a given duration. This, in 
turn, will improve the usage economics especially for drugs that are expensive and difficult 
to extract or to obtain (Brooks eta!., 1980; Tinkelman et al., 1980). 
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1.2 IMPLANTS 
1.2.1 GENERAL PRINCIPLES 
Until the early 1970's, drugs were delivered into the human body mainly via oral and 
intravenous routes. These modes of drug delivery, although still the most common, have 
various disadvantages (Gombotz and Pettie, 1995). Since then considerable effort has been 
devoted into.developing new methods for drug delivery. Some of the most recent modes of 
drug delivery include transdermal drug delivery, pulmonary drug delivery and polymeric 
implants. These polymeric drug delivery is the most extensively studied area as evidenced 
by the number of papers dedicated to this area (Chaubal, 2001 ). 
A polymeric implant is a polymeric matrix imbedded with drug and is surgically planted 
into the body subcutaneously. The drug is then released for absorption into the blood or the 
affected site via diffusion or surface erosion to obtain controlled, predictable and localized 
administration of drugs. The key advantages of polymeric implants are: 
I. Localized delivery of drugs: the preparation can be implanted directly at the site 
where drug action is required and hence systemic exposure of the drug can be 
reduced. This is important especially for toxic drugs, which are associated to 
various systemic side effects. 
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2. Sustained delivery of drugs: Since the drug is released over extended periods, it 
' 
eliminates the need for multiple injections. This feature can improve patient 
compliance especially with drugs for chronic indications that require frequent 
injections. 
3. Stabilization of the drug: The polymer can protect the drug from the physiological 
enviroriment and hence improve its stability in vivo. This particular feature makes 
this technology attractive for the delivery of labile drugs such as proteins. (Gombotz 
and Pettie, 1995; Langer, 1998). 
4. Implants offer an alternative mode for delivering drug into the systemic circulation 
especially with drugs that undergo extensive first pass metabolism. A higher 
amount of drug is capable of reaching the systemic circulation as compared to oral 
dosage forms (Langer, 1998). 
Various synthetic as well as natural polymers have been utilized to form the matrix for the 
implant. The polymers employed should possess suitable characteristics listed below: 
1. The polymer material is biocompatible and biodegradable. The degradation occurs 
in-vivo to smaller fragments, which can then be eliminated from the body either 
through enzymes present in the body (biodegradable polymers) or other chemicals 
(bioabsorbable polymers). Surgical removal is required to remove those non-
biodegredable implants after they are depleted of drugs and thus resulting in 
increased cost and risk of multiple surgeries 
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2. The degradation products of the polymer are nontoxic, non cytotoxic and do not 
cause an inflammatory response. 
3. The degradation should occur within a reasonable period of time as required by the 
application (Swift, 1993). 
Some of the widely usep biodegradable polymers for the fabrication of implants (Bick, 
1983) are listed below. 
Synthetic polymers 
Poly lactic acid 
- Poly-L-lactic acid 
- Poly-D, L-lactic acid 
Poly glycolic acid 
Poly-e-caprolactone 
Poly-p-dioxanon 
Tri-methylen carbonate 
Poly anhydrides 
Poly ortho ester 
Poly urethanes 
Poly amino acids 
Poly hydroxy alcanoates 
Poly phosphazenes 
Poly-b-malein acid 
Natural polymers 
Collagen (Proteins) 
Chitin, Chitosan 
Polysaccharides 
Fibrin 
Albumin 
~ollagen, cellulose and chitosan are the most commonly used natural polymers in the 
nplantable drug delivery system (Tanger, 1986). 
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I .2.2 CONTROLLED RELEASE MECHANISMS INVOLVED IN IMPLANTABLE 
DRUG DELIVERY SYSTEMS 
An ideal implantable drug delivery system exhibits a zero order drug release, in which the 
release of drug is independent of time. However, a constant rate of release is difficult to 
achieve in most cases. As the amount of drug in the delivery system is depleted, the rate of 
release is also reduced. Thus, most drug delivery devices often show two phases of drug 
release: a rapid initial phase (which may or may not be linear) and a slower second phase of 
drug release which relates to the rapid depletion of the drug from the device. 
The mechanisms involved in controlling the release of drugs from the polymeric implants 
include either one or a combination of the followings: 
a. Diffusion 
b. Bioerosion 
::. Osmosis 
)f the three mechanisms, diffusion of the drug through the polymer matrix is the most 
:ommon method involved in controlling the release of drug. The rate of diffusion is 
nfluenced by the size of the drug molecules, porosity of the polymer matrix (total void 
·olume available), degree of crosslinking as well as the swelling characteristics of the 
'olymer (Chaubal, 2001). 
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1. 3 DISSOLUTION OF SUSTAINED RELEASE DOSAGE FORMS 
Drug dissolution is prerequisite to drug absorption and clinical response for almost all 
drugs. It is a process in which the drug is released and is available in solution ready to be 
absorbed. Various dissolution models have been developed over the years to simulate the 
conditions in-vivo and to predict the release of drug upon administration. The rate and 
extent of dissolution may influence the onset, rate, and extent of absorption, and hence 
could have a direct bearing on the pharmacological activity of a drug. 
The earliest reference for dissolution testing was found in the article by Noyes and Whitney 
in 1897. At the middle of the 191h century, the investigations were mainly focused on the 
dissolution behavior of a dosage form and its relation to the biological activity (Javaid, 
1996). A wide variety of dissolution test systems have been described (Ridgway, 1975) and 
these have evolved into two distinct types: the stirred vessel and the flow- through column 
(Nelson and Miller, 1979). The stirred-vessel type is characterized by a relatively large 
volume of fluid with minimal liquid exchange (Langenbucber, 1977). Agitation is 
accomplished by stirring the liquid or by the motion of the vessel. Samplings at appropriate 
time intervals provide a direct measure of the rate and extent of release of the active 
ingredient. In· contrast, the flow-through column method consists of a relatively small 
dissolution cell through which solvent flows through at a constant rate. No additional 
agitaticn is used. 
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The physiochemical characteristics of a sustained release dosage form can affect the rate of 
dissolution. These include wettability of a dosage unit, the penetration ability of the 
dissolution media, as well as the disintegration and degradation of the dosage form 
(Wagner, 1970). Certain dissolution process variables are also important and will affect the 
rate of dissolution (Smollen and Ball, 1984). An agitation rate capable of discriminating in-
vitro conditions, which are important in-vivo, should be sought (Gupta and Robinson, 
1992). The COrifposition" of the dissolution medium should preferably be aqueous in nature 
and capable of maintaining sink condition by keeping the concentration of dissolved drug 
in the bulk medium below 15% of saturation solubility (Swarbrick, 1970). A temperature of 
37°C for the dissolution medium is favoured, being similar to our body temperature. In this 
regard, an allowance of± 0.5°C is deemed acceptable by most compendia. 
Although in-vitro technique offers a cheap and easy mean for evaluation during dosage 
form development, performing in-vivo studies on human or laboratory animal.s are 
necessary. The rate and extent of absorption of the dosage form can be determined by 
pharmacokinetic analysis. The in-vivo studies are necessary to ensure that satisfactory 
bioavailability is obtained without any dose-dumping. 
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1.4 TESTOSTERONE 
1.4.1 GENERAL PHARMACOLOGY 
Figure 1.1 shows the chemical structure of testosterone. Testosterone is the predominant 
sex hormone in males and is produced in the testes. In male, approximately 8 mg of 
testosterone is produ~ed daily and about 95% is produced by the Leydig cells and the 
remaining 5% by the adrenal glands, adrenal cortex and adrenal medulla (Toft et al., 1984). 
1.4.1.1 PHARMACOLOGY 
Testosterone is converted to dihydrotestosterone by the enzyme Sa-reductase in target 
tissues, such as the hypothalamus, and may be of importance in regulating gonadal function 
(Goldfien, 1995). Testosterone promotes growth of the genitalia and the development of 
male secondary sex characteristics. It is necessary for the maintenance of libido and 
potency. Moreover, its presence within the seminiferous tubules is required for 
spermatogenesis. Circulating testosterone, on the other hand, inhibits gonadotrophin 
production by the anterior pituitary, resulting in the suppression of spermatogenesis during 
testosterone therapy. Testosterone also possesses anabolic activity, such as developing and 
maintaining muscle mass. It also helps to prevent osteoporosis (Goldfien, 1995). 
Testosterone or its derivatives are transported to the target tissues, where testosterone enters 
the cell. Circulating testosterone is bound tightly to a serum glycoprotein of hepatic origin, 
called sex hormone binding globulin, and weaklt to albumin. Less than 1% to 2% of the 
circulating testosterone is thought to be unbound. Together the free and weakly bound 
testosterone can enter target tissues (Goldfien, 1995). 
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FIGURE 1.1 : CHEMICAL STRUCTURE OF TESTOSTERONE 
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1.4.1.2 PHARMACOKINETICS 
Although testosterone is readily absorbed orally, considerable first-pass metabolism occurs 
in the liver where inactivation of testosterone occurs. Approximately 80% of the drug is 
metabolized, thus minimal amount of testosterone reaches the systemic circulation after 
oral administration (Gillies et al., 1981; Lipsitt, 1983). Testosterone is normally 
administered as an oily intramuscular injection, which is released slowly to obtain a 
prolonged effect (Paton et al., 1969). A half-life of 4.5 hours has been reported after 
administering testosterone orally, while a half-life of 11 days has been reported after 
intramuscular injection (Paton et al., 1969). 
1.4.1.3 PREPARATIONS 
Oral. Oral preparations of testosterone and its synthetic analogues are minimally absorbed 
due to its extensive first pass metabolism. However, oral administration of fluoxymesterone 
10-20 mg per day is suffice in the middle-aged or elderly patients to alleviate minor 
symptoms of testosterone deficiency and prevent osteoporosis. 
Intramuscular. For testosterone replacement therapy, intramuscular preparations are the 
most effective. Dosage should provide about I 0 mg per day; with testosterone propionate 
this is met by giving 25 mg three times weekly. With the longer acting esters, the dose is 
about 200 mg every 2 to 3 weeks. 
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Implants. Te~tosterone pellets 400-600 mg are inserted subcutaneously every 4-6 months 
into the anterior abdominal wall by means of a trocar and cannula under local anaesthesia. 
(Toft eta/., 1984). 
Transdefmal.: A preparation of testosterone for transdermal use has been developed in 
which a testosterone-loaded film is applied each day to the scrotal skin. This preparation 
permits maintenance of plasma concentrations of testosterone within the normal male range 
(Toft eta/., 1984). 
1.4.1.4 INDICATIONS 
Testosterone is mainly used in the treatment of male hypogonadism, a clinical syndrome 
due to reduced testosterone secretion and may delay puberty in children. However, the 
administration of testosterone should be monitored closely, especially in children, since it 
can cause premature epiphyseal closure, resulting in stunting of growth and short stature. 
Thus, not more than half the adult replacement dose should be used for the first year. 
Moreover, if there is co-existing growth hormone deficiency, testosterone therapy should 
be withheld until an acceptable height is reached with human growth hormone therapy 
(Toft eta/., 1984). 
Testosterone replacement therapy is also used to alleviate minor symptoms of testosterone 
deficiency (e.g. tiredness, lack of concentration and depression) and to prevent 
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osteoporosis. Large doses of testosterone have also been used in the treatment of refractory 
: 
anemias, resulting in an increase in reticulocytosis and hemoglobin levels. 
1.4.1.5 ADVERSE EFFECTS AND CONTRAINDICATIONS 
The side effects observed with testosterone therapy are salt and water retention, 
hypertension, cholestatic jaundice (especially with methyltestosterone and 
fluoxymesterone) and premature closure of the epiphyses if given in early puberty. 
Testosterone is contraindicated in the presence of prostatic carcinoma or breast carcinoma 
in men. It causes virilization in women and suppresses spermatogenesis in men. The use of 
testosterone is also contraindicated in pregnant women or women who may become 
pregnant during the course of the therapy. Care should be exercised in the administration of 
testosterone to patients with renal or cardiac disease who are predisposed to edema. If 
sodium and water retention occurs, it is responsive to diuretic therapy (Toft et al., 1984). 
1.4.2 EVOLUTION OF TESTOSTERONE REPLACEMENT THERAPY 
Testosterone is administered through a wide variety of modalities over the six decades 
since its introduction into clinical usage (Hamilton, 1937). However, the clinical 
applications of testosterone are limited due to their negligible oral bioavailability and 
extremely short half-life when they are administered parenterally (Foss, 1939; Parkes, 
1938). On the other hand, orally active synthetic testosterones, mostly based on the 17-a 
ilkyl substituents, are required at high doses with multiple daily dosing, which is 
17 
unsatisfactory for life-long testosterone therapy. Nevertheless, they are now considered 
I 
obsolete due to their hepatotoxicity. Thus, the main focus of research now is to develop 
effective depot formulations of testosterone (Handelsman et al., 1997). In recent years, 
injections containing ester derivatives of testosterone in oily vehicle have been regarded as 
the standard testosterone replacement therapy (Nieschlag & Behre, 1990). However, this 
form of treatment requires deep, painful intramuscular injections (Mackey et al., 1995) at 
regular intervals of approximately 2 weeks (Snyder & Lawrence, 1980). Moreover, oily 
intramuscular injections of testosterone exhibits prominent fluctuations in the blood 
concentrations (Behre et al., 1990), making this regimen far from ideal for life-long 
testosterone replacement therapy (Lisser et al., 1942; Stuenkel et al., 1991). 
Subdermal implants, originally developed by Deansley and Parkes (1937 and 1938), were 
the first true depot formulations of testosterone and were rapidly accepted into clinical 
practice (Biskind et al., 1941; Hamilton and Dorfman, 1939; Howard and Vest, 1939). The 
original testosterone pellets were formulated by high-pressure compression of testosterone 
mixed with cholesterol. However in the early 1950s, an alternative manufacturing method 
was developed in which the testosterone was melted and cast into a solid cylindrical shape 
on cooling without any excipients (Handelsman, 1990, 1991 ). Fused crystalline implants 
were available 4 decades ago but has since declined in popularity and by 1980, they had 
fallen largely into disuse (Handelsman et al., 1997). However, over the last decades, 
subdermal implants have again saw an increase in popularity due to fewer side effects 
(Cantrill et al., 1984; Conway et al., 1988; Handelsman et al., 1990; Jockenhovel et al., 
1988). Cantrill et al., in 1984, showed that testosterone implantation generally remains as 
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the most acceptable form of androgen replac~ment therapy to both the patients and the 
doctors. 
1.5 EXPERIMENTAL SCOPE OF THIS STUDY 
The study was undertaken to develop a matrix controlled release formulation· of an 
. . 
implantable system using testosterone as a model drug. Various polymers were evaluated as 
the matrix forming material. 
The study was sectioned into various stages with the following objectives. 
• To develop a matrix controlled release implantable system for testosterone. 
• To evaluate various polymers as matrix forming material. 
• To evaluate the in-vivo performance of the formulations using male Sprague-
Dawley male rats. 
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CHAPTER TWO 
PREPARATION OF TESTOSTERONE CONTROLLED RELEASE IMPLANT 
SYSTEMS AND IN-VITRO STUDIES 
2.1: INTRODUCTION 
One of the most commonly used methods for fabricating controlled release dosage forms is 
through incorporating the drug substance into a hydrophilic matrix system. Generally, 
modulation of the drug release is achieved through using different types of polymers 
(Beraja et al., 1987), different viscosity grades of polymer (Nakano et al., 1983) as well as 
soluble and insoluble fillers (Ford et al., 1987; Rao et al., 1990). 
Hydrophilic matrix systems containing water-soluble polymers, such as hydroxypropyl 
methylcellulose (HPMC), were introduced in the early 1970s. The hydrophilic matrix 
system is the most simple sustained release technology, consisting essentially of a drug and 
water-soluble polymer with high viscosity. HPMC has been widely approved for use in 
controlled release systems (Hogan, 1989; Wichterle, 1960; Padley, 1980; Graham, 1984; 
Vazquez et al, 1992) as well as implants, transdermal drug delivery systems and oral-
controlled release systems (Ford et al., 1987). HPMC is inert, stable against microbial 
attack (Nakano et al., 1983) and has good biocompatibility, thus, making it one of the most 
prominent carriers in drug delivery systems (Colombo, 1993). 
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HPMC is capable of swelling in water and retaining a considerable amount of water 
without dissolving in it (Breimer et a/., 1985). The release of drug from the HPMC 
matrices generally involves the simultaneous absorption of water and desorption of drug 
via a swelling-controlled diffusion/erosion mechanism (Lee, 1983; 1984). As water 
penetrates the glassy matrix containing a dispersed drug, the polymer swells and thus, 
lowering the glass transition temperature, leading to the diffusion of drug through this 
swollen rubbery region into the external medium. 
A nu!llber of variables can alter the release of drug from the matrix containing HPMC. The 
release of drug is, to a great extent, controlled by the viscosity of the polymer used. Huber 
and Christensin (1968) found that tablets containing a higher viscosity grade of HPMC 
released tetrazine at a significantly slower rate than that of a lower viscosity grade. 
According .to Ford and co-workers (1985a; 1985b; 1985c) and Xu and Sunada (1995), the 
most important factor affecting the release rate from HPMC matrices is the drug: HPMC 
ratio. Nakano et a/. (1983) indicated that the release of theophylline from HPMC matrices 
decreased as the viscosity grade of the HPMC was increased. The sustained drug release 
from these two systems is achieved through polymer swelling to a gel-like consistency at 
the tablet periphery, thus forming a barrier to drug diffusion. Harwood and Schwartz (1982) 
also found that the release of drug was slower from an ophthalmic matrix preparation 
which contained higher viscosity grades of HPMC. A similar observation was also reported 
by Lapidus and Lordi (1968) and Daly eta/. (1984). 
fhe release of drug from HPMC matrix could also be modified through the incorporation 
>f additional exipients. Saito (1960) reported that the viscosity of non-ionic polymers could 
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be increased by the addition of anionic surfactants. A similar observation was also observed 
by Walker and Wells (1982) who found that a combination of anionic sodium 
carboxymethyl-cellulose with cellulose produced a synergistic increase in viscosity. Daly et 
a/. (1984) also showed similar results when investigating the effect of sodium lauryl sulfate 
(SLS) on the release of chlorpheniramine from HPMC matrix. 
The present study was conducted to develop a controlled release implant system of 
testosterone. Polymers such as starch, HPMC and polyvinyl pyrrolidone (PVP) were used 
(either individually or in combination) to prepare the implant systems and their in-vitro . 
drug release characteristics were evaluated. Moreover, implant systems with increasing 
HPMC content; different viscosity grades of HPMC and those with anionic surfactant, 
sodium lauryl sulphate (SLS), were also evaluated. The above polymers were chosen based 
on their inertness as well as biocompatibility, being important pre-requisites in the 
formulation of implant systems. 
2.2 MATERIALS AND METHODS 
2.2.1 MATERIALS 
Testosterone, Schering, Germany. 
HPMC KIOO, HPMC K4M, HPMC KISM and HPMC KIOOM, Colorcon Company, 
Singapore. 
Polyvinyl pyrrolidone, BASF Company, Germany. 
Maize starch, BDH Chemiclas, England .. 
22 
.) 
LO:\D 
; ··. ·: 
.•·.·. 
; .': .. · 
..... 
' .. ; .·· 
.. :; ... ·. . , .. 
.· .. C.ONT~OL 
·• .. ·· .. • 
·.·. 
. .. 
Figure 2.1 :Front view Illustration of the extruder 
23 
Sodium lauryl sulphate, Shin Poong Phrmaceuticals, Seoul, Korea. 
2.2.2 METHODS 
2.2.2.1 PREPARATION OF TESTOSTERONE IMPLANT SYSTEMS 
Testosterone implant systems were prepared by first mixing the testosterone with polymeric 
materials in a planetary mixer (Kenwood Chef, UK) for 10 minutes. This was followed by 
the addition of sufficient amount of water until a suitable wet mass was formed which was 
then mixed for 15 minutes. The mixture was extruded using a ram extruder (SDX, 
Malaysia) yielding cylindrical implant systems with an outer diameter of I mm. The 
extruder was set to move downwards at a speed of 235 mm/min. For sterilization of the 
final extrudates, the extruded implant systems were then heated at 60°C for 4 hours in an 
oven (Carbo lite, England) (BP, 1988). 
An illustration of the ram extruder is shown in Figure 2.1. The mixture to be extruded was 
inserted into the barrel, which was then hand tightened to the die that contained one or 
more holes with a diameter of I mm. The barrel was then placed onto the table above the 
collection cavity. The plunger started to move downwards into the barrel when the power is 
on, thus pushing the mixture through the hole yielding short cylindrical implant systems. 
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